drugset / Trial / NCT03444584
Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Phase 2 study Comparing the effects on glucose control of MEDI0382 in combination with Dapagliflozin and Metformin compared to placebo in combination with Dapagliflozin and Metformin in overweight/obese participants with Type 2 Diabetes Mellitus (T2DM).
Timeline
- Start
- 2018-05-08
- Primary completion
- 2018-12-06
- Completion
- 2018-12-06
Outcome
Met primary endpoint
registry analysis (superiority test); Placebo vs MEDI0382; p <0.0001; LS mean difference -143.09 (95% CI -198.20 to -87.98); ANCOVA NCT03444584 ↗
registry analysis (superiority test); Placebo vs MEDI0382; p <0.0001; LS mean difference -22.17 (95% CI -30.24 to -14.10); ANCOVA NCT03444584 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cotadutide | Peptide | 300 ug | Subcutaneous |
| Background | Dapagliflozin | Small molecule | 10 mg | Oral |
| Background | Metformin | Small molecule | — | Oral |